Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids01:31

Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids

In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Link Between Venous and Arterial Thrombosis: Is There a Role for Endothelial Dysfunction?

Cells·2025
Same author

Development of Personalized Thrombogenesis and Thrombin Generation Assays to Assess Endothelial Dysfunction in Cardiovascular Diseases.

Biomedicines·2023
Same author

Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis.

Journal of thrombosis and haemostasis : JTH·2021
Same author

Current practices of standardized risk assessment for venous thromboembolism: Results from a global survey from the World Thrombosis Day steering committee.

Journal of thrombosis and haemostasis : JTH·2021
Same author

An update on the global use of risk assessment models and thromboprophylaxis in hospitalized patients with medical illnesses from the World Thrombosis Day steering committee: Systematic review and meta-analysis.

Journal of thrombosis and haemostasis : JTH·2021
Same author

Milvexian for the Prevention of Venous Thromboembolism.

The New England journal of medicine·2021

Related Experiment Video

Updated: Jun 10, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Oral Xa inhibitors.

Erica Romualdi1, Walter Ageno

  • 1Department of Clinical Medicine, University of Insubria, UO Medicina I, Ospedale di Circolo, Varese, Italy.

Hematology/Oncology Clinics of North America
|July 28, 2010
PubMed
Summary
This summary is machine-generated.

New oral direct factor Xa inhibitors offer a promising alternative to current antithrombotic drugs. Clinical trials show favorable results, suggesting these convenient, fixed-dose medications may soon impact clinical practice.

Related Experiment Videos

Last Updated: Jun 10, 2026

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression
07:53

Multidimensional Coculture System to Model Lung Squamous Carcinoma Progression

Published on: March 17, 2020

Area of Science:

  • Pharmacology
  • Hematology
  • Drug Development

Background:

  • Existing antithrombotic drugs often require careful coagulation monitoring and dose adjustments.
  • Factor Xa inhibitors represent a novel class of anticoagulants targeting a key enzyme in the coagulation cascade.

Purpose of the Study:

  • To review advanced oral, direct factor Xa inhibitors.
  • To summarize the results of completed clinical studies on these novel agents.

Main Methods:

  • Literature review of clinical trials and studies on oral direct factor Xa inhibitors.
  • Analysis of drug properties including route of administration, dosing, and monitoring requirements.

Main Results:

  • Several oral direct factor Xa inhibitors demonstrate promising efficacy and safety profiles.
  • These agents offer advantages such as fixed dosing and no need for routine coagulation monitoring.

Conclusions:

  • Oral direct factor Xa inhibitors are potential alternatives to current antithrombotic therapies.
  • Further clinical studies will determine the full impact of these drugs, including rivaroxaban, on clinical practice.